DE3777223D1 - Feste dispersion der substanz fr-900506. - Google Patents

Feste dispersion der substanz fr-900506.

Info

Publication number
DE3777223D1
DE3777223D1 DE8787103716T DE3777223T DE3777223D1 DE 3777223 D1 DE3777223 D1 DE 3777223D1 DE 8787103716 T DE8787103716 T DE 8787103716T DE 3777223 T DE3777223 T DE 3777223T DE 3777223 D1 DE3777223 D1 DE 3777223D1
Authority
DE
Germany
Prior art keywords
substance
fixed dispersion
solid dispersion
dispersion composition
octacos
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE8787103716T
Other languages
English (en)
Inventor
Yoshio Ueda
Fumio Shimojo
Yasuo Shimazaki
Kazutake Kado
Toshiyasu Honbo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Original Assignee
Fujisawa Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co Ltd filed Critical Fujisawa Pharmaceutical Co Ltd
Application granted granted Critical
Publication of DE3777223D1 publication Critical patent/DE3777223D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Cosmetics (AREA)
  • Reinforced Plastic Materials (AREA)
  • Colloid Chemistry (AREA)
DE8787103716T 1986-04-02 1987-03-14 Feste dispersion der substanz fr-900506. Expired - Lifetime DE3777223D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB868608080A GB8608080D0 (en) 1986-04-02 1986-04-02 Solid dispersion composition

Publications (1)

Publication Number Publication Date
DE3777223D1 true DE3777223D1 (de) 1992-04-16

Family

ID=10595572

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8787103716T Expired - Lifetime DE3777223D1 (de) 1986-04-02 1987-03-14 Feste dispersion der substanz fr-900506.

Country Status (16)

Country Link
US (1) US4916138A (de)
EP (1) EP0240773B1 (de)
JP (1) JPS62277321A (de)
KR (2) KR950007209B1 (de)
AT (1) ATE73327T1 (de)
CA (1) CA1302279C (de)
DE (1) DE3777223D1 (de)
DK (1) DK174979B1 (de)
ES (1) ES2032397T3 (de)
GB (1) GB8608080D0 (de)
GR (1) GR3004124T3 (de)
HK (1) HK6397A (de)
IE (1) IE59712B1 (de)
MX (1) MX9202945A (de)
RU (1) RU1826977C (de)
UA (1) UA13209A (de)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5366971A (en) * 1987-11-09 1994-11-22 Sandoz Ltd. Use of 11,28-dioxa-4-azatricyclo[22.3.1.04,9 ]octacos-18-ene derivatives and pharmaceutical compositions containing them
JPH02206A (ja) * 1987-11-11 1990-01-05 Fujisawa Pharmaceut Co Ltd エキシホンと水溶性高分子化合物とを含有することを特徴とする新規製剤
ATE84213T1 (de) * 1987-11-11 1993-01-15 Pharmascience Lab Exifon und ein wasserloesliches polymer enthaltende pharmazeutische zubereitung.
FR2640137A1 (fr) * 1988-12-08 1990-06-15 Texinfine Sa Systemes transporteurs de principes actifs lipophiles et leur procede d'obtention
AU635286B2 (en) * 1989-07-05 1993-03-18 Astellas Pharma Inc. Aqueous liquid composition for external use
US5208228A (en) * 1989-11-13 1993-05-04 Merck & Co., Inc. Aminomacrolides and derivatives having immunosuppressive activity
KR0177158B1 (ko) * 1990-03-01 1999-03-20 후지사와 도모기찌로 면역억제 활성을 갖는 트리사이클릭 화합물 함유 용액 제제
US5316773A (en) * 1990-07-19 1994-05-31 Otsuka Pharmaceutical Co., Ltd. Particulate preparation containing a flourracil derivative and hydroxypropylmethyl-cellulose
US5143918A (en) * 1990-10-11 1992-09-01 Merck & Co., Inc. Halomacrolides and derivatives having immunosuppressive activity
US5147877A (en) * 1991-04-18 1992-09-15 Merck & Co. Inc. Semi-synthetic immunosuppressive macrolides
US5565560A (en) * 1991-05-13 1996-10-15 Merck & Co., Inc. O-Aryl,O-alkyl,O-alkenyl and O-alkynylmacrolides having immunosuppressive activity
US5162334A (en) * 1991-05-13 1992-11-10 Merck & Co., Inc. Amino O-alkyl, O-alkenyl and O-alkynlmacrolides having immunosuppressive activity
US5250678A (en) 1991-05-13 1993-10-05 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylmacrolides having immunosuppressive activity
US5189042A (en) * 1991-08-22 1993-02-23 Merck & Co. Inc. Fluoromacrolides having immunosuppressive activity
US5208241A (en) * 1991-09-09 1993-05-04 Merck & Co., Inc. N-heteroaryl, n-alkylheteroaryl, n-alkenylheteroaryl and n-alkynylheteroarylmacrolides having immunosuppressive activity
AU5434094A (en) * 1992-11-18 1994-06-08 Fujisawa Pharmaceutical Co., Ltd. Prolonged-action pharmaceutical preparation
DE4316537A1 (de) * 1993-05-18 1994-11-24 Basf Ag Zubereitungen in Form fester Lösungen
US5693648A (en) * 1994-09-30 1997-12-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynyl-macrolides having immunosuppressive activity
FR2736550B1 (fr) 1995-07-14 1998-07-24 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
DK0851753T3 (da) 1995-09-19 2004-03-15 Fujisawa Pharmaceutical Co Aerosolpræparater
TW426516B (en) * 1996-12-06 2001-03-21 Fujisawa Pharmaceutical Co An oral pharmaceutical composition in solid dispersion containing water-insoluble tricyclic compounds
CN1259053A (zh) * 1997-04-11 2000-07-05 藤泽药品工业株式会社 药物组合物
SI1064942T1 (en) * 1998-03-26 2004-12-31 Fujisawa Pharmaceutical Co., Ltd. Sustained release preparation of a macrolide
US6410301B1 (en) 1998-11-20 2002-06-25 Kosan Biosciences, Inc. Myxococcus host cells for the production of epothilones
CN100381566C (zh) 1998-11-20 2008-04-16 科森生物科学公司 产生环氧噻酮及其衍生物的重组方法和材料
US20030119029A1 (en) * 1999-04-30 2003-06-26 Regents Of The University Of Michigan Compositions and methods relating to novel benzodiazepine compounds and targets thereof
US20050113460A1 (en) * 1999-04-30 2005-05-26 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
US7572788B2 (en) 1999-04-30 2009-08-11 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
ATE433752T1 (de) 1999-04-30 2009-07-15 Univ Michigan Verwendung von benzodiazepinen zur behandlung von autoimmunischen krankheiten, entzündungen, neoplasien, viralen infektionen und atherosklerosis
US20060025388A1 (en) * 1999-04-30 2006-02-02 Glick Gary D Compositions and methods relating to novel compounds and targets thereof
US7063857B1 (en) 1999-04-30 2006-06-20 Sucampo Ag Use of macrolide compounds for the treatment of dry eye
US20040176358A1 (en) * 1999-04-30 2004-09-09 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
US6562795B2 (en) 2000-02-18 2003-05-13 Kosan Biosciences, Inc. Motilide compounds
US6750047B2 (en) * 2000-08-21 2004-06-15 Kosan Biosciences, Inc. Fermentation and purification of migrastatin and analog
GB0108498D0 (en) * 2001-04-04 2001-05-23 Novartis Ag Organic Compounds
JP2004534812A (ja) * 2001-06-22 2004-11-18 ファイザー・プロダクツ・インク 薬物および中性ポリマーの分散物の医薬組成物
GB0123400D0 (en) 2001-09-28 2001-11-21 Novartis Ag Organic compounds
US6989131B2 (en) * 2002-03-12 2006-01-24 Uop Llc Catalytic reactor with integral evaporator
DE60325377D1 (de) * 2002-08-29 2009-01-29 Pfizer Motilidverbindungen
BRPI0412329A (pt) * 2003-07-09 2006-09-05 Chong Kun Dang Pharm Corp dispersão sólida de tacrolimus e método de processar a mesma
CA2537041C (en) 2003-08-29 2012-04-03 Lifecycle Pharma A/S Modified release compositions comprising tacrolimus
US8591946B2 (en) 2003-08-29 2013-11-26 Veloxis Pharmaceuticals A/S Modified release compositions comprising tacrolimus
US20090275099A1 (en) * 2004-04-27 2009-11-05 Regents Of The University Of Michigan Methods and compositions for treating diseases and conditions associated with mitochondrial function
US20050272723A1 (en) * 2004-04-27 2005-12-08 The Regents Of The University Of Michigan Methods and compositions for treating diseases and conditions associated with mitochondrial function
EP1768662A2 (de) 2004-06-24 2007-04-04 Novartis Vaccines and Diagnostics, Inc. Immunstimulatoren kleiner moleküle und assays für deren nachweis
US20060014677A1 (en) * 2004-07-19 2006-01-19 Isotechnika International Inc. Method for maximizing efficacy and predicting and minimizing toxicity of calcineurin inhibitor compounds
US20060052369A1 (en) * 2004-09-07 2006-03-09 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
AU2006203946B2 (en) * 2005-01-03 2009-07-23 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
KR100678824B1 (ko) * 2005-02-04 2007-02-05 한미약품 주식회사 용해성이 증가된 무정형 타크로리무스 고체분산체 및 이를포함하는 약제학적 조성물
CA2611031A1 (en) 2005-06-01 2007-05-10 The Regents Of The University Of Michigan Unsolvated benzodiazepine compositions and methods
US20070105844A1 (en) * 2005-10-26 2007-05-10 Regents Of The University Of Michigan Therapeutic compositions and methods
NZ568254A (en) 2005-11-01 2011-06-30 Univ Michigan 1,4-Benzodiazepine-2,5-diones for regulating cell death and treating autoimmune diseases
GB0602632D0 (en) * 2006-02-08 2006-03-22 Pliva Istrazivacki Inst D O O Preparation Of A Solid Dosage From Comprising Tacrolimus And/Or Sirolimus
US7759338B2 (en) * 2006-04-27 2010-07-20 The Regents Of The University Of Michigan Soluble 1,4 benzodiazepine compounds and stable salts thereof
NZ573452A (en) 2006-06-09 2011-09-30 Univ Michigan Compositions and methods relating to novel compounds and targets thereof
US20080181947A1 (en) * 2006-09-26 2008-07-31 Astellas Pharma Inc. Controlled release dosage form of tacrolimus
WO2008084698A1 (ja) 2006-12-28 2008-07-17 Astellas Pharma Inc. タクロリムス徐放性医薬組成物
US7851465B2 (en) 2007-03-09 2010-12-14 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
CA2688381C (en) 2007-05-30 2016-10-11 Lifecycle Pharma A/S Once daily oral dosage form comprising tacrolimus
CN101855203B (zh) 2007-09-14 2014-03-19 密执安州立大学董事会 F1f0-atp合成酶抑制剂以及相关的方法
TW200932240A (en) 2007-10-25 2009-08-01 Astellas Pharma Inc Pharmaceutical composition containing lipophilic substance which inhibits IL-2 production
RU2010122902A (ru) 2007-11-06 2011-12-20 Дзе Риджентс оф дзе Юниверсити оф Мичиган (US) Бензодиапениноновые соединения, применимые в лечении кожных состояний
CL2008000374A1 (es) * 2008-02-05 2008-04-04 Igloo Zone Chile S A Composicion farmaceutica que comprende un polvo para suspension oral de tacrolimus o una de sus sales, hidratos o solvatos y excipientes farmaceuticamente aceptables; procedimiento de preparacion de dicha composicion farmaceutica; y uso para la preve
KR101003042B1 (ko) 2008-03-17 2010-12-21 종근당바이오 주식회사 고순도 타크로리무스의 정제 방법
US8222272B2 (en) * 2008-04-11 2012-07-17 Roxane Laboratories, Inc. Pharmaceutical formulation and process comprising a solid dispersion of macrolide (tacrolimus)
US8497307B2 (en) 2008-09-11 2013-07-30 The Regents Of The University Of Michigan Aryl guanidine F1F0-ATPase inhibitors and related methods
WO2010121164A2 (en) 2009-04-17 2010-10-21 The Regents Of The University Of Michigan 1,4-benzodiazepinone compounds and their use in treating cancer
JP2013505258A (ja) 2009-09-18 2013-02-14 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン ベンゾジアゼピノン化合物およびそれを使用する治療方法
WO2011062765A2 (en) 2009-11-17 2011-05-26 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties
AU2010322287B2 (en) 2009-11-17 2014-04-03 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties
HUE028847T2 (en) 2010-02-17 2017-01-30 Veloxis Pharmaceuticals As Stabilized tacrolimus preparation
WO2011157721A2 (en) 2010-06-14 2011-12-22 Ratiopharm Gmbh Ivabradine-containing pharmaceutical composition
WO2012026896A1 (en) 2010-08-25 2012-03-01 Les Laboratoires Medis Sa Surface modified micronized tacrolimus crystalline particles and pharmaceutical compositions thereof
KR101243938B1 (ko) * 2010-10-19 2013-03-19 이희엽 타크롤리무스를 유효성분으로 함유하는 서방형 펠렛
JP6185559B2 (ja) 2012-04-11 2017-08-23 ダウ グローバル テクノロジーズ エルエルシー 有機希釈剤およびセルロースエーテルを含む組成物
KR20160058840A (ko) * 2013-09-25 2016-05-25 다우 글로벌 테크놀로지스 엘엘씨 유기 액체 희석제 및 특정의 하이드록시알킬 메틸셀룰로오스를 포함하는 조성물
WO2016078481A1 (zh) * 2014-11-21 2016-05-26 杭州领业医药科技有限公司 一种含他克莫司的药物组合物及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL130099C (de) * 1963-10-11
DE1492034A1 (de) * 1965-05-18 1969-02-20 Merck Ag E Verfahren zur Herstellung fester haltbarer Zubereitungen von empfindlichen,in Wasser schwer loeslichen Wirkstoffen,vorzugsweise Arzneimitteln
US3852421A (en) * 1970-03-23 1974-12-03 Shinetsu Chemical Co Excipient and shaped medicaments prepared therewith
GB1322306A (en) * 1971-04-15 1973-07-04 Meiji Seika Co Stabilized antibiotic preparation and manufacturing process therefor
US4127647A (en) * 1975-04-08 1978-11-28 Meiji Seika Kaisha, Ltd. Process for preparation of stable amorphous macrolide antibiotic solids
GB1593261A (en) * 1976-07-23 1981-07-15 Inveresk Res Int Controlled release suppository
GB1579818A (en) * 1977-06-07 1980-11-26 Yamanouchi Pharma Co Ltd Nifedipine-containing solid preparation composition
DE3013839A1 (de) * 1979-04-13 1980-10-30 Freunt Ind Co Ltd Verfahren zur herstellung einer aktivierten pharmazeutischen zusammensetzung
CA1146866A (en) * 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
US4259314A (en) * 1979-12-10 1981-03-31 Hans Lowey Method and composition for the preparation of controlled long-acting pharmaceuticals
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
JPS6038322A (ja) * 1983-08-11 1985-02-27 Fujisawa Pharmaceut Co Ltd ジヒドロピリジンａ物質含有易溶性固形製剤
US4894366A (en) * 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same

Also Published As

Publication number Publication date
ATE73327T1 (de) 1992-03-15
GB8608080D0 (en) 1986-05-08
IE59712B1 (en) 1994-03-23
KR950007209B1 (ko) 1995-07-04
JPH0536411B2 (de) 1993-05-31
GR3004124T3 (de) 1993-03-31
EP0240773A1 (de) 1987-10-14
HK6397A (en) 1997-01-24
KR950007210B1 (ko) 1995-07-04
UA13209A (uk) 1997-02-28
RU1826977C (ru) 1993-07-07
DK140487A (da) 1987-10-03
US4916138A (en) 1990-04-10
CA1302279C (en) 1992-06-02
JPS62277321A (ja) 1987-12-02
EP0240773B1 (de) 1992-03-11
DK174979B1 (da) 2004-04-05
DK140487D0 (da) 1987-03-18
KR870010073A (ko) 1987-11-30
IE870843L (en) 1987-10-02
MX9202945A (es) 1992-07-01
KR890001626A (ko) 1989-03-28
ES2032397T3 (es) 1993-02-16

Similar Documents

Publication Publication Date Title
DE3777223D1 (de) Feste dispersion der substanz fr-900506.
DK0474126T3 (de)
AU653556B2 (en) Suspendible composition and process for preparing the same
ES2134860T3 (es) Preparacion farmaceutica de accion prolongada.
GR3015245T3 (en) Aqueous liquid formulations.
GR3014946T3 (en) Aqueous liquid composition for external use.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: ASTELLAS PHARMA INC., TOKIO/TOKYO, JP